On 17 July 2013, orphan designation (EU/3/13/1157) was granted by the European Commission to Voisin Consulting SARL, France, for S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one for the treatment of follicular lymphoma.

The sponsorship was transferred to Abbvie Ltd., United Kingdom, in November 2015.

Key facts

Active substance
Disease / condition
Treatment of follicular lymphoma
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Abbvie Ltd
Abbvie House 
Vanwall Business Park
Vanwall Road
Berkshire SL6 4UB
United Kingdom
Tel. +44 (0)1628 644501
Fax +44 (0)1628 672566

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating